Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.

CONCLUSIONS: Tralokinumab 300 mg in combination with TCS as needed was effective and well tolerated in patients with moderate-to-severe AD. PMID: 33000503 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33000503?dopt=Abstract

Source: The British Journal of Dermatology - September 29, 2020 Category: Dermatology Authors: Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, Hijnen D, Jensen TN, Bang B, Olsen CK, Kurbasic A, Weidinger S Tags: Br J Dermatol Source Type: research